AR055999A1 - Derivados de piridofuropirimidina,composiciones farmaceuticas que los contienen,usos en terapeutica y metodo de preparacion - Google Patents
Derivados de piridofuropirimidina,composiciones farmaceuticas que los contienen,usos en terapeutica y metodo de preparacionInfo
- Publication number
- AR055999A1 AR055999A1 ARP060103191A ARP060103191A AR055999A1 AR 055999 A1 AR055999 A1 AR 055999A1 AR P060103191 A ARP060103191 A AR P060103191A AR P060103191 A ARP060103191 A AR P060103191A AR 055999 A1 AR055999 A1 AR 055999A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- groups
- alkoxy
- atom
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- -1 amino, hydroxy Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000005124 aminocycloalkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Estos compuestos son inhibidores potentes y selectivos de la fosfodiesterasa 4 (PDE4), y son por tanto utiles en el tratamiento, la prevencion o la supresion de afecciones patologicas, enfermedades y trastornos conocidos por ser susceptibles de mejora mediante la inhibicion de PDE4. Reivindicacion 1: Un derivado de piridofuropirimidina de formula (1) en la que: G1 representa un grupo seleccionado de -CR6R7- y -O- en el que R6 y R7 representan independientemente átomos de H o grupos alquilo C1-4; R1 y R2 se seleccionan independientemente de átomos de H y grupos alquilo C1-4; R3 representa un grupo seleccionado de alquilo C1-4, alcoxi C1-4, amino, hidroxi, monoalquil C1-4-amino, dialquil C1-4-amino, cicloalquil C3-8-amino, arilo, heteroarilo y grupos heterocíclicos que contienen N saturados que están unidos al anillo de piridina a través de su átomo de N, estando todos ellos opcionalmente sustituidos con uno o más sustituyentes seleccionados del grupo constituido por átomos de halogeno y grupos hidroxi, alquilo C1-4, alcoxi C1-4-alquilo C1-4, arilalquilo C1-4, -O(CO)OR8, alcoxi C1-4, -(CO)NR8R9, -CN, -CF3, -NR8R9, -SR8 y -SO2NH2, representando independientemente cada R8 y R9 un átomo de H o un grupo alquilo C1- 4; R4 y R5 se seleccionan independientemente del grupo constituido por átomos de H, grupos alquilo C1-4, grupos hidroxialquilo C1-4 y grupos de formula (2) -(CR10R11)p-A-(CR12R13)q-G2 en la que p y q son enteros seleccionados de 0, 1, 2 y 3; A es un enlace directo o un grupo seleccionado de -CONR14-, -NR14CO-, -O-, -COO-, -OCO-, -S-, -SO- y -SO2-, representando independientemente cada R10, R11, R12, R13 y R14 un átomo de H o un grupo alquilo C1-4 y siendo G2 un grupo seleccionado de grupos arilo, heteroarilo, o heterociclilo; estando opcionalmente sustituido el grupo G2 con uno o más sustituyentes seleccionados del grupo constituido por átomos de halogeno y grupos alquilo C1-4, hidroxi, oxo, alcoxi C1-4-alquilo C1-4, arilalquilo C1-4, -(CO)OR16, alcoxi C1-4, -(CO)NR16R17, -CN, -CF3, -NR16R17, -SR16 y -SO2NH2; representando independientemente cada R16 y R17 un átomo de H o un grupo alquilo C1-4, y las sales y N-oxidos farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200501840A ES2281251B1 (es) | 2005-07-27 | 2005-07-27 | Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055999A1 true AR055999A1 (es) | 2007-09-12 |
Family
ID=36121512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103191A AR055999A1 (es) | 2005-07-27 | 2006-07-25 | Derivados de piridofuropirimidina,composiciones farmaceuticas que los contienen,usos en terapeutica y metodo de preparacion |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080221096A1 (es) |
| EP (1) | EP1913003A1 (es) |
| JP (1) | JP2009502832A (es) |
| KR (1) | KR20080039384A (es) |
| CN (1) | CN101263144A (es) |
| AR (1) | AR055999A1 (es) |
| AU (1) | AU2006278857A1 (es) |
| CA (1) | CA2616424A1 (es) |
| EC (1) | ECSP088108A (es) |
| ES (1) | ES2281251B1 (es) |
| IL (1) | IL188724A0 (es) |
| MX (1) | MX2008001034A (es) |
| NO (1) | NO20081009L (es) |
| PE (1) | PE20070237A1 (es) |
| RU (1) | RU2008107030A (es) |
| TW (1) | TW200738730A (es) |
| WO (1) | WO2007017078A1 (es) |
| ZA (1) | ZA200800352B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| EP2226323A1 (en) * | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
| CN102898432A (zh) * | 2011-07-29 | 2013-01-30 | 山东轩竹医药科技有限公司 | 三并环化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2360933T3 (es) * | 2000-04-27 | 2011-06-10 | Astellas Pharma Inc. | Derivados de heteroarilo condensados. |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| ES2259892B1 (es) * | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
| ES2259891B1 (es) * | 2004-11-30 | 2007-11-01 | Laboratorios Almirall S.A. | Nuevos derivados de piridotienopirimidina. |
-
2005
- 2005-07-27 ES ES200501840A patent/ES2281251B1/es not_active Expired - Fee Related
-
2006
- 2006-07-21 KR KR1020087002113A patent/KR20080039384A/ko not_active Application Discontinuation
- 2006-07-21 EP EP06762762A patent/EP1913003A1/en not_active Withdrawn
- 2006-07-21 RU RU2008107030/04A patent/RU2008107030A/ru not_active Application Discontinuation
- 2006-07-21 WO PCT/EP2006/007218 patent/WO2007017078A1/en active Application Filing
- 2006-07-21 AU AU2006278857A patent/AU2006278857A1/en not_active Abandoned
- 2006-07-21 US US11/996,781 patent/US20080221096A1/en not_active Abandoned
- 2006-07-21 CA CA002616424A patent/CA2616424A1/en not_active Abandoned
- 2006-07-21 CN CNA2006800338219A patent/CN101263144A/zh active Pending
- 2006-07-21 JP JP2008523200A patent/JP2009502832A/ja active Pending
- 2006-07-21 MX MX2008001034A patent/MX2008001034A/es not_active Application Discontinuation
- 2006-07-25 PE PE2006000897A patent/PE20070237A1/es not_active Application Discontinuation
- 2006-07-25 AR ARP060103191A patent/AR055999A1/es unknown
- 2006-07-27 TW TW095127490A patent/TW200738730A/zh unknown
-
2008
- 2008-01-10 IL IL188724A patent/IL188724A0/en unknown
- 2008-01-11 ZA ZA200800352A patent/ZA200800352B/xx unknown
- 2008-01-16 EC EC2008008108A patent/ECSP088108A/es unknown
- 2008-02-27 NO NO20081009A patent/NO20081009L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101263144A (zh) | 2008-09-10 |
| KR20080039384A (ko) | 2008-05-07 |
| TW200738730A (en) | 2007-10-16 |
| ZA200800352B (en) | 2008-12-31 |
| US20080221096A1 (en) | 2008-09-11 |
| NO20081009L (no) | 2008-02-27 |
| WO2007017078A1 (en) | 2007-02-15 |
| ES2281251A1 (es) | 2007-09-16 |
| MX2008001034A (es) | 2008-03-14 |
| JP2009502832A (ja) | 2009-01-29 |
| CA2616424A1 (en) | 2007-02-15 |
| ECSP088108A (es) | 2008-02-20 |
| EP1913003A1 (en) | 2008-04-23 |
| PE20070237A1 (es) | 2007-04-21 |
| ES2281251B1 (es) | 2008-08-16 |
| RU2008107030A (ru) | 2009-09-10 |
| AU2006278857A1 (en) | 2007-02-15 |
| IL188724A0 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051686A1 (es) | Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4. | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| WO2006078621A3 (en) | 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR062900A1 (es) | Derivados de isoquinolina y de quinazolina utiles como inhibidores de quinasa rho | |
| RU2440991C2 (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| DE602007005811D1 (de) | 6-substituierte isochinolinderivate als rock-1-inhibitoren | |
| AR049696A1 (es) | Derivados de indol | |
| MA50065B1 (fr) | Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53 | |
| AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
| AR050617A1 (es) | Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR049739A1 (es) | Derivados de aril-piridina | |
| PE20081480A1 (es) | Derivados de 8-oxoadenina como inmunomoduladores | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
| AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
| RS54425B1 (en) | Pyridine and Pyrazine Derivatives for Cystic Fibrosis (CF) Treatment | |
| AR049433A1 (es) | Derivados de naftalina | |
| AR066781A1 (es) | Compuestos de imidazopirimidina inhibidores de cinasa | |
| TW200508212A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | |
| AR054081A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |